Search results
Results from the WOW.Com Content Network
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s November 21, 2024 at 12:28 PM If you have a loved one with Alzheimer’s disease, you may have read about a newly ...
The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating ...
Credit - Getty Images. 2023 was a strong year for innovative new drugs, with new medications for Alzheimer’s disease, weight loss, and the first treatment based on the gene-editing technology ...
An Alzheimer’s disease drug may soon have a new dosing schedule. The medication, Leqembi, is currently administered via an infusion every two weeks. Under the proposed changes, the medication ...
BLAZE was a phase II study that also concluded in 2014 and evaluated the effects of crenezumab in patients with mild-to-moderate Alzheimer's Disease, however its primary endpoint was changes in brain amyloid load, with secondary endpoints of changes in other biomarkers, cognition, global function, and activities of daily living. The resultant ...
With full FDA approval for the groundbreaking Alzheimer’s drug Leqembi, Medicare coverage takes a big step forward into a new era of treatment.
A dozen things to know about the new Alzheimer's drug. On July 5, the FDA fully approved Lecanemab (brand name: Leqembi) as a treatment for patients in the early stages of Alzheimer's disease.